Efficacy and safety of oliceridine treatment in patients with postoperative pain: a systematic review and meta-analysis of randomized controlled trials

References

• Kaye AD, Cornett EM, Patil SS, et al. New opioid receptor modulators and agonists. Best Pract Res Clin Anaesthesiol. 2018;32(2):125–136. DOI:10.1016/j.bpa.2018.06.009
   PubMed Web of Science ®Google Scholar
• Gan TJ. Poorly controlled postoperative pain: prevalence, consequences, and prevention. J Pain Res. 2017;10:2287–2298.
   PubMed Web of Science ®Google Scholar
• Hammer GB, Khanna AK, Michalsky C, et al. Oliceridine exhibits improved tolerability compared to morphine at equianalgesic conditions: exploratory analysis from two phase 3 randomized placebo and active controlled trials. Pain Ther. 2021;10(2):1343–1353. DOI:10.1007/s40122-021-00299-0
   PubMed Web of Science ®Google Scholar
• Linder JA, Berman SK. Prescription opioid use, misuse, and use disorders in U.S. Adults. Ann Intern Med. 2018;168(5):382–383.
   PubMed Web of Science ®Google Scholar
• Tan HS, Habib AS. Safety evaluation of oliceridine for the management of postoperative moderate-to-severe acute pain. Expert Opin Drug Saf. 2021;20(11):1291–1298.
   PubMed Web of Science ®Google Scholar
• DeWire SM, Yamashita DS, Rominger DH, et al. A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J Pharmacol Exp Ther. 2013;344(3):708–717. DOI:10.1124/jpet.112.201616
   PubMed Web of Science ®Google Scholar
• Urits I, Viswanath O, Orhurhu V, et al. The utilization of mu-opioid receptor biased agonists: oliceridine, an opioid analgesic with reduced adverse effects. Curr Pain Headache Rep. 2019;23(5):31. DOI:10.1007/s11916-019-0773-1
   PubMed Web of Science ®Google Scholar
• Viscusi ER, Webster L, Kuss M, et al. A randomized, phase 2 study investigating TRV130, a biased ligand of the μ-opioid receptor, for the intravenous treatment of acute pain. Pain. 2016;157(1):264–272. DOI:10.1097/j.pain.0000000000000363
   PubMed Web of Science ®Google Scholar
• Singla N, Minkowitz HS, Soergel DG, et al. A randomized, Phase IIb study investigating oliceridine (TRV130), a novel µ-receptor G-protein pathway selective (μ-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty. J Pain Res. 2017;10:2413–2424.
   PubMed Web of Science ®Google Scholar
• Viscusi ER, Skobieranda F, Soergel DG, et al. APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the µ-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy. J Pain Res. 2019;12:927–943.
   PubMed Web of Science ®Google Scholar
• Singla NK, Skobieranda F, Soergel DG, et al. APOLLO-2: A randomized, placebo and active-controlled phase III study investigating oliceridine (trv130), a g protein-biased ligand at the μ-opioid receptor, for management of moderate to severe acute pain following abdominoplasty. Pain Pract. 2019;19(7):715–731. DOI:10.1111/papr.12801
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Rev Esp Cardiol (Engl Ed). 2021;74(9):790–799. DOI:10.1016/j.recesp.2021.06.016
   PubMed Web of Science ®Google Scholar
• Cumpston M, Li T, Page MJ, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019;10:Ed000142.
   PubMed Web of Science ®Google Scholar
• Welsch P, Petzke F, Klose P, et al. Opioids for chronic osteoarthritis pain: an updated systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks double-blind duration. Eur J Pain. 2020;24(4):685–703.
   PubMed Web of Science ®Google Scholar
• Alyoubi RA, Alshareef AA, Aldughaither SM, et al. Efficacy and safety of mirogabalin treatment in patients with diabetic peripheral neuropathic pain: a systematic review and meta-analysis of randomised controlled trials. Int J Clin Pract. 2021;75(5):e13744. DOI:10.1111/ijcp.13744
   PubMed Web of Science ®Google Scholar
• Jarzyna D, Jungquist CR, Pasero C, et al. American Society for Pain Management Nursing guidelines on monitoring for opioid-induced sedation and respiratory depression. Pain Manag Nurs. 2011;12(3):118–145.e110. DOI:10.1016/j.pmn.2011.06.008
   PubMed Web of Science ®Google Scholar
• Oderda GM, Senagore AJ, Morland K, et al. Opioid-related respiratory and gastrointestinal adverse events in patients with acute postoperative pain: prevalence, predictors, and burden. J Pain Palliat Care Pharmacother. 2019;33(3–4):82–97. DOI:10.1080/15360288.2019.1668902
   PubMed Web of Science ®Google Scholar
• Shafi S, Collinsworth AW, Copeland LA, et al. Association of Opioid-Related Adverse Drug Events with Clinical and Cost Outcomes Among Surgical Patients in a Large Integrated Health Care Delivery System. JAMA Surg. 2018;153(8):757–763. DOI:10.1001/jamasurg.2018.1039
   PubMed Web of Science ®Google Scholar
• Nicholson BD. Economic and clinical burden of opioid-induced nausea and vomiting. Postgrad Med. 2017;129(1):111–117.
   PubMed Web of Science ®Google Scholar
• Gan TJ, Wase L. Oliceridine, a G protein-selective ligand at the μ-opioid receptor, for the management of moderate to severe acute pain. Drugs Today (Barc). 2020;56(4):269–286.
   PubMed Web of Science ®Google Scholar
• Weingarten TN, Warner LL, Sprung J. Timing of postoperative respiratory emergencies: when do they really occur? Curr Opin Anaesthesiol. 2017;30(1):156–162.
   PubMed Web of Science ®Google Scholar
• Jin Z, Lee C, Zhang K, et al. Safety of treatment options available for postoperative pain. Expert Opin Drug Saf. 2021;20(5):549–559.
   PubMed Web of Science ®Google Scholar